[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an exercise-and-sell trading pattern in March 2026. She exercised stock options for a total of 68,328 shares of Common Stock at exercise prices of $6.55 and $12.14 per share, then sold 81,342 shares in open-market transactions.
The sales occurred on March 6, 9 and 10, 2026 at weighted-average prices including $15.14, $14.79 and $14.68 per share. All transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 643,471 shares of Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 81,342 shares ($1,211,737)
Net Sell
15 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
81,342 shs ($1.21M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 400 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $6.55 | $96K |
| Exercise | Common Stock | 400 | $12.14 | $5K |
| Sale | Common Stock | 19,460 | $14.68 | $286K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 11,881 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $6.55 | $96K |
| Exercise | Common Stock | 11,881 | $12.14 | $144K |
| Sale | Common Stock | 30,941 | $14.79 | $458K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 11,881 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $6.55 | $96K |
| Exercise | Common Stock | 11,881 | $12.14 | $144K |
| Sale | Common Stock | 30,941 | $15.14 | $468K |
Holdings After Transaction:
Stock Option (right to buy) — 106,993 shares (Direct);
Common Stock — 662,531 shares (Direct)
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.83 to $15.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $15.15, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.22 to $15.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option is fully vested and exercisable.
